Endocrine status in elderly men with lower urinary tract symptoms: Correlation of age, hormonal status, and lower urinary tract function

Urology

Volumn 55, Issue 3, 2000, Pages 397-402

  Schatzl, Georg ^d   Brössner, Clemens ^b   Schmid, Stefan ^c   Kugler, Walter ^d   Roehrich, Michaela ^e   Treu, Thomas ^f   Szalay, Andras ^g   Djavan, Bob ^a   Schmidbauer, Christian P ^h   Söregi, Stefan ^a   Madersbacher, Stephan ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Oberwart Hospital   (Austria)

^c Institut für Röntgendiagnostik   (Austria)

^d Krankhs der Barmherzigen Schwestern ^*

^e DANUBE HOSPITAL   (Austria)

^f Army Hospital   (Austria)

^g KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^h Allgemeine Poliklinik   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROLACTIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; AGING; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOCRINE FUNCTION; ESTRADIOL BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPOGONADISM; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSTATE HYPERTROPHY; RESIDUAL URINE; TESTIS SIZE; TESTOSTERONE BLOOD LEVEL; ULTRASOUND; URINARY TRACT DISEASE; UROFLOWMETRY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DEHYDROEPIANDROSTERONE; ESTRADIOL; FOLLICLE STIMULATING HORMONE; GONADAL STEROID HORMONES; HUMANS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PROSTATE; PROSTATIC HYPERPLASIA; URINATION DISORDERS; URODYNAMICS;

EID: 0343048346     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00473-2     Document Type: Article

References (22)

1. Oishi K., Boyle P., Barry M.J., et al. Epidemiology and natural history of benign prostatic hyperplasia. Denis L., Griffiths K., Khoury S., et al. Fourth International Consultation on Benign Prostatic Hyperplasia (BPH). 1998;25-59 Health Publication Distributors, Plymouth, United Kingdom.
2. Madersbacher S., Haidinger G., Temml C., et al. The prevalence of lower urinary tract symptoms in Austria as assessed by an open survey of 2096 men. Eur Urol. 34:1998;136-141.
3. Garraway W.M., Collins G.N., Lee R.J. High prevalence of benign prostatic hypertrophy in the community. Lancet. 338:1991;469-471.
4. Griffiths K., Eaton C.L., Harper M.E., et al. Steroid hormones and the pathogenesis of benign prostatic hyperplasia. Eur Urol. 20:(suppl 2):1991;68-77.
5. Lee C. Role of androgen in prostate growth and regression stromal-epithelial interaction . Prostate. 6:(suppl):1996;52-56.
6. Gooren L.J.G. The age-related decline of androgen levels in men clinically significant? Br J Urol. 78:1996;763-768.
7. Gray A., Feldman H.A., McKinlay J.B., et al. Age, middle, and changing sex hormone levels in middle-aged men results of the Massachusetts male aging study . J Clin Endocrinol Metab. 73:1991;1016-1025.
8. Marberger M.J. Long-term effects of finasteride in patients with benign prostatic hyperplasia a double-blind, placebo-controlled, multicenter study . Urology. 51:1998;677-686.
9. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 338:1998;557-563.
10. Suzuki K., Ito K., Ichinose Y., et al. Endocrine environment of benign prostatic hyperplasia prostate size and volume are correlated with serum estrogen concentration . Scand J Urol Nephrol. 29:1995;65-68.
11. Lagiouo P., Mantzoros C.S., Tzonou A., et al. Serum steroids in relation to benign prostatic hyperplasia. Oncology. 54:1997;497-501.
12. Monda J.M., Myers R.P., Bostwick D.G., et al. The correlation between serum prostate-specific antigen and prostate cancer is not influenced by the serum testosterone concentration. Urology. 46:1995;62-64.
13. Partin A.W., Oesterling J.E., Epstein J.I., et al. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol. 145:1991;405-409.
14. Gann P.H., Hennekens C.H., Longcope C., et al. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate. 26:1995;40-49.
15. Krieg M., Nass R., Tunn S. Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab. 77:1993;375-381.
16. Dirnhofer S., Berger C., Hermann M., et al. Coexpression of gonadotropin hormones and their corresponding FSH- and LH/CG-receptors in the human prostate. Prostate. 35:1998;212-220.
17. Madersbacher S., Stulnig T., Huber L., et al. Serum glycoprotein hormones and the free α-subunit in a healthy elderly ageing population - analyses with ultrasensitive time resolved fluoroimmunoassays. Mech Ageing Dev. 71:1993;223-233.
18. Bardin C.W., Swerdloff R.S., Santen R.J. Androgens risks and benefits . J Clin Endocrinol Metab. 73:1991;4-7.
19. Bhasin S. Androgen treatment of hypogonadal men. J Clin Endocrinol Metab. 74:1992;1221-1224.
20. Vermeulen A. Androgens in the aging male. J Clin Endocrinol Metab. 73:1991;221-224.
21. Vermeulen A., Kaufman J.M. Ageing of the hypothalamo-pituitary-testicular axis in men. Horm Res. 43:1995;25-28.
22. Swaab D.F. Ageing of the human hypothalamus. Horm Res. 43:1995;8-11.